hcpcs data

J9289

Injection, nivolumab, 2 mg and hyaluronidase-nvhy

Medicare: Carrier judgmentJ seriesAdded July 01, 2025

What J9289 means

J9289 (Inj nivolumab 2 mg hyaluron) belongs to the HCPCS Level II J series (Drugs Administered Other than Oral Method; Chemotherapy Drugs). Its Medicare coverage status is Carrier judgment. Medicare coverage is left to the judgment of the local Medicare Administrative Contractor (MAC), so check your MAC's local coverage determinations.

Part B pricing: Drugs.

Code details

Short description
Inj nivolumab 2 mg hyaluron
Coverage code
C = Carrier judgment
Pricing indicator
51 = Drugs
Multiple pricing indicator
A = Not applicable as HCPCS priced under one methodology
Type of service
1 = Medical care
Action code
A = Add procedure or modifier code
Action effective date
July 01, 2025
Code added date
July 01, 2025
Data year
2026

Questions about J9289

What is HCPCS code J9289?

HCPCS code J9289 is a Level II code in the J series (Drugs Administered Other than Oral Method; Chemotherapy Drugs). Its full description is: "Injection, nivolumab, 2 mg and hyaluronidase-nvhy"

Is J9289 a CPT code?

No. J9289 is a HCPCS Level II code maintained by CMS, not a CPT (Level I) code from the American Medical Association. People often search for it as a CPT code because both code sets are reported on the same claims.

Does Medicare cover HCPCS code J9289?

The Medicare coverage code for J9289 is "Carrier judgment". Medicare coverage is left to the judgment of the local Medicare Administrative Contractor (MAC), so check your MAC's local coverage determinations.

When was HCPCS code J9289 added?

J9289 was added to the HCPCS code set on July 01, 2025. The most recent action on it (Add procedure or modifier code) took effect on July 01, 2025.

All J codes